p53-based cancer therapy.

MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer (2013) 3.60

Translating p53 into the clinic. Nat Rev Clin Oncol (2010) 2.55

p53 Research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol (2010) 2.34

TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature (2015) 2.33

Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget (2011) 2.28

MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med (2012) 1.93

p53 regulation by ubiquitin. FEBS Lett (2011) 1.51

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. J Med Chem (2014) 1.21

Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov (2013) 1.17

Translational approaches targeting the p53 pathway for anti-cancer therapy. Br J Pharmacol (2012) 1.04

p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance. Front Oncol (2012) 1.04

p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans. EMBO Mol Med (2012) 1.04

Bioinformatics and variability in drug response: a protein structural perspective. J R Soc Interface (2012) 1.01

PCAF ubiquitin ligase activity inhibits Hedgehog/Gli1 signaling in p53-dependent response to genotoxic stress. Cell Death Differ (2013) 1.00

p53 Acetylation: Regulation and Consequences. Cancers (Basel) (2014) 0.97

Negative regulation of p53 by Ras superfamily protein RBEL1A. J Cell Sci (2013) 0.92

Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following Chemotherapy. Clin Med Insights Oncol (2015) 0.90

Small molecule compounds targeting the p53 pathway: are we finally making progress? Apoptosis (2014) 0.90

Inactivation and inducible oncogenic mutation of p53 in gene targeted pigs. PLoS One (2012) 0.89

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. Onco Targets Ther (2014) 0.89

Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. Pharmgenomics Pers Med (2015) 0.88

Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo. Sci Rep (2015) 0.88

Dominant effects of Δ40p53 on p53 function and melanoma cell fate. J Invest Dermatol (2013) 0.87

P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation. World J Gastroenterol (2015) 0.86

Novel Perspectives on p53 Function in Neural Stem Cells and Brain Tumors. J Oncol (2010) 0.86

p53 abnormalities and potential therapeutic targeting in multiple myeloma. Biomed Res Int (2014) 0.85

Ubiquitylation of p53 by the APC/C inhibitor Trim39. Proc Natl Acad Sci U S A (2012) 0.85

What's that gene (or protein)? Online resources for exploring functions of genes, transcripts, and proteins. Mol Biol Cell (2014) 0.84

SIRT1 is involved in oncogenic signaling mediated by GPER in breast cancer. Cell Death Dis (2015) 0.83

Interplay between p53 and VEGF: how to prevent the guardian from becoming a villain. Cell Death Differ (2013) 0.81

Recent progress in targeting cancer. Aging (Albany NY) (2011) 0.80

Functional repair of p53 mutation in colorectal cancer cells using trans-splicing. Oncotarget (2015) 0.80

Identification of 5-Iodotubercidin as a genotoxic drug with anti-cancer potential. PLoS One (2013) 0.80

Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53. PLoS One (2013) 0.80

Nanoscale label-free bioprobes to detect intracellular proteins in single living cells. Sci Rep (2014) 0.79

OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol (2017) 0.78

Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B. Cytotechnology (2014) 0.78

Loss of HSF1 results in defective radiation-induced G(2) arrest and DNA repair. Radiat Res (2011) 0.78

Dynamics of DNA damage induced pathways to cancer. PLoS One (2013) 0.78

Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion. Cancer Invest (2011) 0.78

Proteasome inhibition mediates p53 reactivation and anti-cancer activity of 6-gingerol in cervical cancer cells. Oncotarget (2015) 0.78

Essential Roles of E3 Ubiquitin Ligases in p53 Regulation. Int J Mol Sci (2017) 0.77

An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cells. Virology (2015) 0.77

Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential. BMC Cancer (2015) 0.76

Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors. PLoS One (2014) 0.76

Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape. Cell Biochem Funct (2015) 0.76

RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway. BMC Cancer (2014) 0.76

Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy. Mol Ther Oncolytics (2017) 0.75

Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy. Oncolytic Virother (2016) 0.75

Effects of recombinant human adenovirus-p53 on the regression of hepatic fibrosis. Int J Mol Med (2016) 0.75

Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a dominant negative breast cancer xenograft model. Gene Ther (2014) 0.75

Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death. Oncotarget (2015) 0.75

Efficacy of recombinant human adenovirus-p53 combined with chemotherapy for locally advanced cervical cancer: A clinical trial. Oncol Lett (2017) 0.75

NEURL4 regulates the transcriptional activity of tumor suppressor protein p53 by modulating its oligomerization. Oncotarget (2017) 0.75

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53

hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell (2001) 15.97

Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell (2001) 15.05

Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62

Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science (1999) 12.52

The p53-mdm-2 autoregulatory feedback loop. Genes Dev (1993) 11.19

Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature (1995) 10.18

Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 9.48

Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A (2003) 9.14

Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun (2000) 9.09

Mammalian sirtuins--emerging roles in physiology, aging, and calorie restriction. Genes Dev (2006) 8.48

The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell (2003) 8.34

mdm2 expression is induced by wild type p53 activity. EMBO J (1993) 8.01

Sirtuins in mammals: insights into their biological function. Biochem J (2007) 7.60

Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J (2002) 6.37

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 5.97

Modeling the therapeutic efficacy of p53 restoration in tumors. Cell (2006) 5.95

Modelling Myc inhibition as a cancer therapy. Nature (2008) 5.81

SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell (2008) 5.76

Acetylation is indispensable for p53 activation. Cell (2008) 5.70

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med (2004) 5.48

Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol (1993) 5.31

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med (2002) 5.18

Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell (2008) 5.11

Direct inhibition of the NOTCH transcription factor complex. Nature (2009) 4.82

A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J (1999) 4.68

The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One (2008) 4.32

Negative regulation of the deacetylase SIRT1 by DBC1. Nature (2008) 4.29

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A (2008) 4.07

Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol (1998) 3.99

Pharmacological rescue of mutant p53 conformation and function. Science (1999) 3.91

Signaling to p53: ribosomal proteins find their way. Cancer Cell (2009) 3.84

A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev (1996) 3.61

Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet (2006) 3.54

Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell (2008) 3.38

Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol (2006) 3.37

Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci U S A (2006) 3.35

A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science (2001) 3.35

The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol (2000) 3.25

How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer (2008) 3.17

An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat Cell Biol (2000) 3.07

Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci U S A (2004) 3.06

SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res (2007) 2.98

Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem (2006) 2.95

Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res (2005) 2.94

Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res (2006) 2.92

An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol (2006) 2.91

Sirtuins--novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov (2008) 2.89

Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem (2001) 2.80

Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem (2005) 2.77

Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc (2007) 2.71

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A (2009) 2.61

Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res (2008) 2.51

Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med (1996) 2.51

Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet (1987) 2.48

An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene (2000) 2.36

MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell (2009) 2.36

Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev (2006) 2.35

Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene (2002) 2.34

Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell (2006) 2.32

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci U S A (2008) 2.30

Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst (1996) 2.28

Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol (1997) 2.25

Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem (2005) 2.23

Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci U S A (2001) 2.23

Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J Mol Cell Cardiol (2007) 2.22

Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood (2007) 2.16

Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle (2004) 2.15

Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia (2005) 2.15

PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell (2009) 2.09

C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol (2001) 2.09

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res (2005) 2.07

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell (2004) 2.05

Phase I trial of elactocin. Br J Cancer (1996) 2.01

The Sirtuin family: therapeutic targets to treat diseases of aging. Curr Opin Chem Biol (2008) 2.00

Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res (2009) 2.00

Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol (1998) 1.99

The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer (2009) 1.97

Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell (2005) 1.96

Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci U S A (2009) 1.94

Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene (1994) 1.94

Function of the SIRT1 protein deacetylase in cancer. Biotechnol J (2007) 1.88

Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell (2003) 1.88

Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem (2010) 1.85

Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci U S A (2006) 1.80

Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene (2006) 1.78

Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene (2008) 1.78

Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene (2008) 1.76

Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol Cell Biol (2006) 1.76

An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp Cell Res (1999) 1.74

Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation. Nat Cell Biol (2007) 1.73

Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp Cell Res (2001) 1.73

Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res (2006) 1.73

Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle (2009) 1.64

In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721). Cancer Chemother Pharmacol (1986) 1.60

MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol (2007) 1.59

HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene (2007) 1.59

Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer (2009) 5.12

Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget (2010) 1.62

Mdm2 and p53 are highly conserved from placozoans to man. Cell Cycle (2010) 1.51

The Mdm2 and p53 genes are conserved in the Arachnids. Cell Cycle (2010) 1.36

Ribosomal protein S3: A multi-functional protein that interacts with both p53 and MDM2 through its KH domain. DNA Repair (Amst) (2009) 1.35

Therapeutic exploitation of the p53 pathway. Trends Mol Med (2002) 1.15

Sirtuins and p53. Adv Cancer Res (2009) 1.10

Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion. EMBO Rep (2012) 1.03

Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6. FEBS Lett (2003) 1.03

Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. J Med Chem (2009) 1.02

Pilot screening programme for small molecule activators of p53. Int J Cancer (2005) 0.95

Oligomerization of the human ARF tumor suppressor and its response to oxidative stress. J Biol Chem (2003) 0.91

Synthesis and biological characterisation of sirtuin inhibitors based on the tenovins. Bioorg Med Chem (2012) 0.88

Selective induction of apoptosis by leptomycin B in keratinocytes expressing HPV oncogenes. Int J Cancer (2007) 0.86

New insights into p53 based therapy. Discov Med (2011) 0.86

Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based phenotypic screen. Cell Cycle (2008) 0.85

Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6. Sci Rep (2013) 0.85

p53 contributes to T cell homeostasis through the induction of pro-apoptotic SAP. Cell Cycle (2012) 0.80

Discovery and validation of SIRT2 inhibitors based on tenovin-6: use of a ¹H-NMR method to assess deacetylase activity. Molecules (2012) 0.78

Protecting normal cells from the cytotoxicity of chemotherapy. Cell Cycle (2012) 0.78

Leptomycin B induces apoptosis in cells containing the whole HPV 16 genome. Int J Oncol (2009) 0.77

Drug discovery in the p53 field. Semin Cancer Biol (2010) 0.77

Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Mol Cancer (2014) 0.76